<DOC>
	<DOCNO>NCT02380443</DOCNO>
	<brief_summary>This single center , open label dose frequency escalation study InSituVax personalize anti-tumor vaccine protocol combine cryoablation select metastatic lesion intra-lesional immunotherapy AlloStim® . The in-situ ( body ) cancer vaccine step combine kill single metastatic tumor lesion use cryoablation order cause release tumor-specific marker immune system inject bioengineered allogeneic immune cell ( AlloStim® ) lesion adjuvant order modulate immune response educate immune system kill tumor cell ever reside body .</brief_summary>
	<brief_title>Increased Frequency AlloStim® Immunotherapy Dosing Combination With Cryoablation Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Colorectal cancer ( CRC ) rank third common cancer worldwide . Metastasis main reason death CRC patient . The current drug use treat colorectal cancer provide important treatment option patient , limitation include drug resistance , poor efficacy severe side effect . Development new therapeutic strategy KRAS mutant well BRAF mutant tumor therefore highly need order offer new category drug ( immunotherapy ) . This study target population mCRC patient progress two line chemotherapy eligible targeted therapy . The study assess six different dose schedule . A standard 3 plus 3 study design use . The starting frequency dose schedule escalate subsequent group patient . The study evaluate safety increase frequency AlloStim® dose anti-tumor effect new propose dose frequency schedule .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Adult male female subject age 1880 year screen visit 2 . Pathologically confirm diagnosis colorectal adenocarcinoma 3 . Presenting metastatic disease : Primary intact previously resect Metastatic lesion ( ) liver must nonresectable Extrahepatic disease acceptable 4 . At least one liver lesion able visualize ultrasound determine safely assessable percutaneous cryoablation 5 . Previous treatment failure two previous line active systemic chemotherapy : Previous chemotherapy must include oxaliplatincontaining ( e.g . FOLFOX ) irinotecancontaining ( e.g . FOLFIRI ) regimen without bevacizumab administer adjuvant set treatment metastatic disease If KRAS wild type , must least one prior antiEGFR therapy Treatment failure due disease progression toxicity Disease progression second line therapy must document radiologically must occur within 30 day follow last administration treatment metastatic disease 6 . ECOG performance score : 01 7 . Adequate hematological function : Absolute granulocyte count ≥ 1,200/mm3 Platelet count ≥ 100,000/mm3 PT/INR ≤ 1.5 correctable &lt; 1.5 time interventional procedure Hemoglobin ≥ 9 g/dL ( may correct transfusion ) 8 . Adequate Organ Function : Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Aspartate aminotransferase ( AST ) ( SGOT ) ≤ 2.5 time ULN Alanine aminotransferase ( ALT ) ( SGPT ) ≤ 2.5 time ULN 9 . EKG without clinically relevant abnormality 10 . Female subject : Not pregnant lactate 11 . Patients child bear potential must agree use adequate contraception 12 . Study specific inform consent native language subject . 1 . Bowel obstruction high risk obstruction 2 . Moderate severe ascites require medical intervention 3 . Clinical evidence radiological evidence brain metastasis leptomeningeal involvement 4 . Symptomatic asthma COPD 5 . Pulmonary lymphangitis symptomatic pleural effusion ( grade ≥ 2 ) result pulmonary dysfunction require active treatment oxygen saturation &lt; 92 % room air 6 . Bevacizumab ( Avastin® ) treatment within 6 week schedule cryoablation procedure 7 . Regorafenib prior Study Period 8 . Taking anticoagulant medication concomitant medical condition ( unless safely discontinue invasive cryoablation , biopsy intratumoral injection procedure ) 9 . Prior allogeneic bone marrow/stem cell solid organ transplant 10 . Chronic use ( &gt; 2 week ) great physiologic dos corticosteroid agent ( dose equivalent &gt; 5 mg/day prednisone ) within 30 day first day study drug treatment Topical corticosteroid permit 11 . Prior diagnosis active autoimmune disease ( e.g. , rheumatoid arthritis , multiple sclerosis , autoimmune thyroid disease , uveitis ) . Well control Type I diabetes allow 12 . Prior experimental therapy 13 . History blood transfusion reaction 14 . Known allergy bovine product 15 . Progressive viral bacterial infection All infection must resolve subject must remain afebrile seven day without antibiotic prior place study 16 . Cardiac disease symptomatic nature 17 . History HIV positivity AIDS 18 . Concurrent medication know interfere platelet function coagulation ( e.g. , aspirin , ibuprofen , clopidogrel , warfarin ) unless medication discontinue appropriate time period base drug halflife know activity ( e.g. , aspirin 7 day ) prior cryoablation biopsy procedures 19 . History severe hypersensitivity monoclonal antibody drug contraindication study drug 20 . Psychiatric addictive disorder condition , opinion investigator , would preclude study participation . 21 . Subjects lack ability provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>KRAS mutant</keyword>
	<keyword>BRAF mutant</keyword>
	<keyword>metastatic</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>AlloStim®</keyword>
	<keyword>cryoablation</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>immunotherapy</keyword>
</DOC>